Survival-signaling pathway as a promising target for cancer chemotherapy

The serine/threonine kinase AKT, also known as PKB or RAC-PK, is a key molecule for protecting cells from undergoing apoptosis. Several studies have suggested that the AKT-mediated survival-signaling pathway is an attractive target for cancer chemotherapy: (1) the AKT pathway is relatively inactive in resting cells; (2) amplification of the AKT gene occurs in some tumors; (3) loss of the tumor suppressor gene PTEN (phosphatase and tensin homolog deleted on chromosome 10) is common in tumors and its loss constitutively activates AKT; (4) AKT is activated at the cancer invasion front. To clarify which drugs exhibit their cytotoxicity by inhibiting the AKT pathway, we screened anticancer drugs that could downregulate phospho-AKT levels and AKT kinase activity. We found that UCN-01 (7-hydroxystaurosporine), heat-shock protein 90 (HSP90) inhibitors, and topotecan (10-hydroxy-9-dimethylaminomethyl-(S)-camptothecin) possessed the ability to interfere with the AKT pathway. UCN-01 directly suppressed upstream AKT kinase 3-phosphoinositide-dependent protein kinase-1 (PDK1) (IC50 <33 nM) both in vitro and in tumor xenografts. HSP90 inhibitors and topotecan suppressed AKT activity via indirectly downregulating PDK1 and phosphatidylinositide-3-OH kinase activities. Transfection of the constitutively active AKT complementary DNA into cells attenuated the cytotoxic effects of the drugs, indicating that inhibition of the AKT pathway plays an important role in exerting their cytotoxic effects. These results strongly suggest that the AKT-mediated survival-signaling pathway is a promising and attractive target for cancer chemotherapy.

[1]  B. A. Ballif,et al.  Disruption of 3-Phosphoinositide-dependent Kinase 1 (PDK1) Signaling by the Anti-tumorigenic and Anti-proliferative AgentN-α-tosyl-l-phenylalanyl Chloromethyl Ketone* , 2001, The Journal of Biological Chemistry.

[2]  T. Tsuruo,et al.  Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis , 2000, Journal of cellular physiology.

[3]  H. Cohen,et al.  Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  T. Tsuruo,et al.  Modulation of Akt kinase activity by binding to Hsp90. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Hsu,et al.  The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2* , 2000, The Journal of Biological Chemistry.

[6]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[7]  J. Laine,et al.  The protooncogene TCL1 is an Akt kinase coactivator. , 2000, Molecular cell.

[8]  A. Ishida,et al.  Involvement of Hsp90 in Signaling and Stability of 3-Phosphoinositide-dependent Kinase-1* , 2002, The Journal of Biological Chemistry.

[9]  N. Rosen,et al.  Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2 , 2002, Oncogene.

[10]  T. Tsuruo,et al.  Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. , 2000, Cancer research.

[11]  B. Vanhaesebroeck,et al.  The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.

[12]  R. Tibbetts,et al.  Trypanosoma cruzi heat-shock protein 90 can functionally complement yeast. , 1995, Molecular and biochemical parasitology.

[13]  Brian A. Hemmings,et al.  Carboxyl-Terminal Modulator Protein (CTMP), a Negative Regulator of PKB/Akt and v-Akt at the Plasma Membrane , 2001, Science.

[14]  C M Croce,et al.  Tcl1 enhances Akt kinase activity and mediates its nuclear translocation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Andjelkovic,et al.  Insulin-stimulated Protein Kinase B Phosphorylation on Ser-473 Is Independent of Its Activity and Occurs through a Staurosporine-insensitive Kinase* , 2001, The Journal of Biological Chemistry.

[16]  T. Tsuruo,et al.  Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine) , 2002, Oncogene.

[17]  T. Tsuruo,et al.  Domain Mapping Studies Reveal That the M Domain of hsp90 Serves as a Molecular Scaffold to Regulate Akt-Dependent Phosphorylation of Endothelial Nitric Oxide Synthase and NO Release , 2002, Circulation research.

[18]  T. Tsuruo,et al.  The Cleavage of Akt/Protein Kinase B by Death Receptor Signaling Is an Important Event in Detachment-induced Apoptosis* , 2001, The Journal of Biological Chemistry.

[19]  S. Akinaga,et al.  Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. , 1991, Cancer research.

[20]  Takashi Tsuruo,et al.  Akt-dependent Phosphorylation of p27Kip1Promotes Binding to 14-3-3 and Cytoplasmic Localization* , 2002, The Journal of Biological Chemistry.

[21]  Takashi Tsuruo,et al.  Topotecan inhibits VEGF‐ and bFGF‐induced vascular endothelial cell migration via downregulation of the PI3K‐Akt signaling pathway , 2002, International journal of cancer.

[22]  Takashi Tsuruo,et al.  Regulation of Kinase Activity of 3-Phosphoinositide-dependent Protein Kinase-1 by Binding to 14-3-3* , 2002, The Journal of Biological Chemistry.

[23]  M. Cumming,et al.  Antiangiogenic potential of camptothecin and topotecan , 1999, Cancer Chemotherapy and Pharmacology.